PMS Registry
Company Name
AbbVie Biopharmaceuticals GmbH Taiwan Branch
Protocol Number
H19-940
Title of Study
Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD)
Primary Objective
To describe the multidimensional burden of disease, treatment patterns, and health care resource utilization in adolescent and adult patients with moderate to severe AD.
Number of Sites
2
Period of Study
From:2020/01/01 to:2021/12/31
Number of Patients
25人
IRB Approval Date
NTUH: 2020/02/19
CSMUH: not yet
Publication Plan / Date